MXCT vs TMO · rev $38.6M vs P/E 24, rev $44.56B
MaxCyte Inc (MXCT) versus Thermo Fisher Scientific Inc (TMO) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
Thermo Fisher Scientific Inc (TMO) is a diagnostics & research company listed on US.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported TMO revenue for 2025-12-31 was $44.56B. Net income was $6.70B. Revenue was up 3.9% from 2024-12-31 to 2025-12-31. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
MXCT currently screens at market cap $124.3M. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
Not investment advice. Open the MXCT and TMO stock pages for the full models.
Not investment advice.